Food and Drug Administration, HHS.
Notice of public workshop.
The Food and Drug Administration (FDA, we) is announcing the following pubic workshop entitled “Improving the Implementation of Risk-Based Monitoring Approaches of Clinical Investigations.” This public workshop is convened by Duke University's Robert J. Margolis, MD, Center for Health Policy and supported by a cooperative agreement with FDA. The purpose of the public workshop is to capture stakeholder experiences with risk-based approaches to monitoring of clinical investigations and gather stakeholder input on opportunities to further the implementation of risk-based approaches to monitoring.
The public workshop will be held on July 17, 2019, from 8:30 a.m. to 5 p.m. See the SUPPLEMENTARY INFORMATION section for registration date and information.
The public workshop will be held at the Marriott Marquis Washington, DC at 901 Massachusetts Ave. NW, in Washington DC. For additional travel and hotel information, please refer to the following website: https://healthpolicy.duke.edu/events/improving-implementation-risk-based-monitoring-approaches-clinical-trials. There will also be a live webcast for those unable to attend the meeting in person (see Streaming Webcast of the Public Workshop).
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Raymond Chiang, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 2232, Silver Spring, MD 20993, 301-796-1940, Raymond.Chiang@fda.hhs.gov.
End Further Info
Start Supplemental Information
To support greater implementation of risk-based approaches to monitoring (RBM) of clinical investigations, FDA issued draft guidance for industry in March 15, 2019 (84 FR 9531) entitled “A Risk-Based Approach to Monitoring of Clinical Investigations: Questions and Answers, “ which is available at https://www.fda.gov/media/121479/download. This draft guidance expands on the guidance for industry entitled, “Oversight of Clinical Investigations—A Risk-Based Approach to Monitoring” (August 2013) by providing additional guidance to facilitate sponsors' implementation of risk-based monitoring.
Traditionally, sponsors and research organizations have depended upon on-site monitoring and 100 percent source data verification for each clinical site, an approach that is resource intensive and may contribute to increased clinical trial costs. Adoption of RBM could lead to improvements to human subject protections, data integrity, and the efficiency of clinical investigations.
Data suggest that RBM has not yet been widely implemented. Therefore, FDA is seeking additional feedback from stakeholders on the challenges, barriers, and enablers that might be impacting the adoption of RBM. The public workshop addressed in this document is being held to capture stakeholder experiences with risk-based approaches to monitoring of clinical investigations and to gather stakeholder input on ways to improve the implementation of risk-based approaches to monitoring.
II. Topics for Discussion at the Public Workshop
During the public workshop, speakers and participants will cover a range of issues related to implementation of risk-based approaches to monitoring. Topics for discussion will include, and are not limited to, challenges to implementation of RBM, enablers to support implementation of RBM, and lessons learned from strategies employed to implement RBM.
III. Participating in the Public Workshop
Registration: To register for the public workshop, complete the registration form at https://healthpolicy.duke.edu/events/improving-implementation-risk-based-monitoring-approaches-clinical-trials. Please provide complete contact information for each attendee, including name, title, affiliation, address, email, and telephone.
Registration is free and based on space availability, with priority given to early registrants. Persons interested in attending this public workshop must register online by July 16, 2019, by 5 p.m. Eastern Time. Early registration is recommended because seating is limited; therefore, FDA may limit the number of participants from each organization. Registrants will receive confirmation when they have been registered. If time and space permit, onsite registration on the day of the public workshop will be provided beginning at 8 a.m. We will let registrants know if registration closes before the day of the public workshop.
If you need special accommodations due to a disability, please contact the Duke-Margolis Center for Health Policy (phone: 202-791-9561, email: email@example.com) no later than July 10, 2019.
Streaming Webcast of the Public Workshop: This public workshop will also be webcast and archived video footage will be available at the event website. Persons interested in viewing the live webcast are encouraged to register in advance (see Registration). The live webcast will also be available at the website above on the day of the event without preregistration. Registered webcast participants will be sent technical system requirements in advance of the event. It is recommended that you review these technical system requirements prior to joining the streaming webcast of the public workshop.
FDA has verified the website addresses in this document, as of the date this document publishes in the Federal Register, but websites are subject to change over time.
Meeting Materials: All event materials will be provided to registered attendees via email prior to the workshop and will be publicly available at the Duke-Margolis Center for Health Policy website: https://healthpolicy.duke.edu/Start Printed Page 25282events/improving-implementation-risk-based-monitoring-approaches-clinical-trials.
Transcripts: Please be advised that transcripts of the public workshop will not be available.
End Supplemental Information
Dated: May 28, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-11411 Filed 5-30-19; 8:45 am]
BILLING CODE 4164-01-P